Skye Bioscience (SKYE) Stock Analysis

What Skye Bioscience does

Skye Bioscience, Inc., a clinical-stage biotechnology company, focuses on developing molecules that modulate G-protein-coupled receptors (GPCRs) to treat obesity, overweight, and metabolic diseases. Its lead product candidate is nimacimab, a peripherally restricted negative allosteric modulating antibody targeting cannabinoid receptor 1, a key GPCR involved in metabolic regulation. The company was formerly known as Emerald Bioscience, Inc. and changed its name to Skye Bioscience, Inc. in January 2021. Skye Bioscience, Inc. is headquartered in San Diego, California.

Key metrics

ETFs linked to SKYE

Broad-market and Healthcare sector ETFs an investor holding Skye Bioscience is often also exposed to. Open an ETF page to see its actual top holdings.

PortView Portfolio Insights

PortView analyzes how SKYE fits your actual portfolio — position weight, portfolio concentration, unrealized gain/loss, contribution to return, sector exposure, indirect exposure through the ETFs you hold, and correlation with your other holdings. Connect a portfolio to see your personalized figures; PortView never shows another user's private holdings.

Similar companies

Frequently asked questions

What is the ticker symbol for Skye Bioscience?

Skye Bioscience trades under the ticker SKYE on NASDAQ.

Which exchange is SKYE listed on?

SKYE is listed on NASDAQ.

What sector does Skye Bioscience operate in?

Skye Bioscience is classified in the Healthcare sector (Biotechnology industry).

How can PortView help analyze SKYE in a portfolio?

PortView shows SKYE's weight in your portfolio, its contribution to return and risk, sector exposure, indirect exposure through ETFs you own, and correlation with your other holdings.